secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-096983
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health Q2 2024 net loss $17.2M; Revita gets FDA Breakthrough Device designation
--------------------------------------------------------------------------------

- Net loss of $17.2M vs $30.2M in Q2 2023; cash and equivalents $102.4M as of June 30, 2024.
- FDA Breakthrough Device designation for Revita in weight maintenance after GLP-1 discontinuation.
- REMAIN-1 pivotal study for Revita initiated; open label data expected Q4 2024; midpoint analysis Q2 2025.
- REVITALIZE-1 on track to report topline data mid-2025 in expanded T2D population (protocol amendment approved).
- Chairman Allan Will stepped down; Ajay Royan appointed new Chair effective August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024096983/0000950170-24-096983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024096983/guts-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer